Selection of biologics for patients with metastatic colorectal cancer: The role of predictive markers

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 3, 2015, Pages 273-276

  Kasi, Pashtoon Murtaza ^a   Hubbard, Joleen M ^a   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

aflibercept; bevacizumab; biologics; cetuximab; EGFR; metastatic colorectal cancer; panitumumab; RAS; regorafenib; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MICRORNA; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; RAS PROTEIN;

CANCER SURVIVAL; COLORECTAL SURGERY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG TARGETING; EDITORIAL; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SELECTION; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES; COLORECTAL NEOPLASMS; GENETICS; METASTASIS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOLOGICAL FACTORS; BIOMARKERS; CETUXIMAB; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; RAS PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 84923306691     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1001743     Document Type: Editorial

References (24)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677-83
2. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37
3. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863): 303-12
4. Wasan H, Meade AM, Adams R, et al. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol 2014;15(6):631-9
5. Mitchell EP, Piperdi B, Lacouture ME, et al. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. Clin Colorectal Cancer 2011;10(4):333-9
6. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19(7):1902-12
7. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1023-34
8. Ciardiello F, Lenz H-J, Kohne CH, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. J Clin Oncol Meeting Abstracts 2014;32(15 suppl); abstr 3506
9. Bokemeyer C, Kohne C-H, Ciardiello F, et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. J Clin Oncol Meeting Abstracts 2014;32(15 Suppl):abstr 3505
10. Cervantes A. Exploring better strategies for EGFR antibodies in colon cancer. Lancet Oncol 2014;15(6):549-50
11. Sartore-Bianchi A, Fieuws S, Veronese S, et al. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol 2012;65(3):218-23
12. Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013;24(10):2554-9
13. Hansen TF, Christensen Rd, Andersen RF, et al. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial. Br J Cancer 2013;109(5):1243-51
14. Liu Y, Starr MD, Bulusu A, et al. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013;2(2): 234-42
15. Hansen TF, Christensen Rd, Andersen RF, et al. The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis 2012;27(6):715-20
16. Johnsson A, Hagman H, Frödin JE, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial. Ann Oncol 2013;24(9):2335-41
17. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24(19):3061-8
18. Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014;123(5):640-6
19. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15(6):601-11
20. Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30(15):1755-62
21. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065-75
22. Venook PA, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC. J Clin Oncol Meeting Abstracts 2014 32;5s; (Suppl); abstr LBA3
23. Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol 2012;13(3): 233-4
24. Berlin J. Beyond exon 2-the developing story of RAS mutations in colorectal cancer. N Engl J Med 2013;369(11):1059-60